Nova Mentis Life Science Corp.: Nova Mentis Files Patent on

mRNA Diagnostic Index to Measure Drug Treatment Response
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or

Related Keywords

Italy , United States , Canada , Rome , Lazio , United Kingdom , Vancouver , British Columbia , British , Canadian , Marvins Hausman , Viviana Trezza , Instagram , Twitter , Nova Mentis Life Science Corp , British Columbia Newsfile Corp , Trademark Office , Neither The Canadian Securities Exchange , European Union , Facebook , Canadian Securities Exchange , Measure Drug Treatment , Mentis Life Science , Fragilex Conference , Fragilex Syndrome , Market Regulator , Nova Mentis Life Science , Nova , Eventis , Life , Science , Orp , Files , Patent , Sdiagnosing , Monitoring , Reating , Neurological , Diseases , Psychoactive , Tryptamine , Derivatives ,